Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) have earned an average rating of “Hold” from the eighteen analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $23.05.
Several research firms recently weighed in on ACOR. Oppenheimer set a $21.00 price target on Acorda Therapeutics and gave the stock a “hold” rating in a report on Friday, February 16th. ValuEngine raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Piper Jaffray Companies raised Acorda Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $25.10 to $37.00 in a report on Thursday, February 15th. Goldman Sachs Group raised Acorda Therapeutics from a “sell” rating to a “neutral” rating in a report on Wednesday, February 7th. Finally, HC Wainwright set a $34.00 price target on Acorda Therapeutics and gave the stock a “buy” rating in a report on Monday, November 20th.
Shares of Acorda Therapeutics (NASDAQ ACOR) traded up $0.80 during midday trading on Wednesday, hitting $26.10. The stock had a trading volume of 458,410 shares, compared to its average volume of 753,328. The company has a debt-to-equity ratio of 0.64, a current ratio of 3.07 and a quick ratio of 2.81. Acorda Therapeutics has a one year low of $13.60 and a one year high of $33.00. The company has a market cap of $1,220.00, a P/E ratio of -5.39 and a beta of 1.63.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.88 by ($0.27). The firm had revenue of $188.40 million for the quarter, compared to analyst estimates of $171.70 million. Acorda Therapeutics had a negative return on equity of 4.88% and a negative net margin of 37.97%. The business’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.05 earnings per share. equities analysts predict that Acorda Therapeutics will post -0.41 EPS for the current fiscal year.
In other Acorda Therapeutics news, insider David Lawrence sold 31,000 shares of Acorda Therapeutics stock in a transaction on Friday, January 19th. The stock was sold at an average price of $27.58, for a total value of $854,980.00. Following the completion of the transaction, the insider now directly owns 5,275 shares of the company’s stock, valued at approximately $145,484.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Burkhard Blank sold 11,050 shares of Acorda Therapeutics stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.53, for a total value of $226,856.50. Following the completion of the transaction, the insider now directly owns 33,150 shares of the company’s stock, valued at $680,569.50. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Meadow Creek Investment Management LLC raised its holdings in Acorda Therapeutics by 56.0% in the 4th quarter. Meadow Creek Investment Management LLC now owns 8,736 shares of the biopharmaceutical company’s stock valued at $187,000 after acquiring an additional 3,136 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new position in Acorda Therapeutics in the 2nd quarter valued at $199,000. Crossmark Global Holdings Inc. acquired a new position in Acorda Therapeutics in the 3rd quarter valued at $233,000. Teacher Retirement System of Texas acquired a new position in Acorda Therapeutics in the 4th quarter valued at $347,000. Finally, Voya Investment Management LLC raised its holdings in Acorda Therapeutics by 10.1% in the 2nd quarter. Voya Investment Management LLC now owns 20,633 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 1,897 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/21/acorda-therapeutics-inc-acor-given-average-recommendation-of-hold-by-brokerages.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.